Product Sales Net was Harrow’s largest product and service line in fiscal 2025, bringing in $271.91M of $272.30M (100%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Product Sales Net | $83.52M | $117.45M | $198.62M | $271.91M | |||||
| Product Sales, Net | — | — | — | — | |||||
| Other Revenue | — | $12.75M | — | $394.00K | |||||
| Commissions | $3.87M | — | — | — | |||||
| Transfer Of Acquired Product Sales Profits | $1.21M | — | — | — | |||||
| Other Revenues | — | — | $995.00K | — | |||||
| Transfer Of Profit | — | — | — | — | |||||
| License Revenues | — | — | — | — | |||||
| License | — | — | — | — | |||||
| Total | $88.60M | $130.19M | $199.61M | $272.30M |
Harrow brought in $272.30M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Harrow regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $199.61M. Product Sales Net was the largest at $271.91M (99.9%), ahead of Other Revenue at $394.00K (0.1%).
Harrow began breaking out Other Revenue in fiscal 2023, when it brought in $12.75M. Harrow stopped reporting Commissions ($3.87M in fiscal 2022), Transfer Of Acquired Product Sales Profits ($1.21M in fiscal 2022) and Other Revenues ($995.00K in fiscal 2024) as separate lines.
Branded was Harrow’s largest segment in fiscal 2025, bringing in $195.76M of $272.30M (72%).
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Branded | $50.26M | $116.12M | $195.76M | |||
| Imprimisrx | $79.94M | $83.50M | $76.55M | |||
| Pharmaceutical Compounding | — | — | — | |||
| Total | $130.19M | $199.61M | $272.30M |
Harrow brought in $272.30M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 36.4% from $199.61M in fiscal 2024. Branded was the largest at $195.76M (71.9%), ahead of Imprimisrx at $76.55M (28.1%).
Compared with fiscal 2024, Branded grew 68.6% to $195.76M, while Imprimisrx fell 8.3% to $76.55M. From fiscal 2023 to 2025, combined revenue from these segments grew from $130.19M to $272.30M, a compound annual growth rate of 44.6%. Branded's share of the total rose from 38.6% to 71.9%.
Harrow (HROW) reports its revenue by product and service and by segment. In fiscal 2025, Product Sales Net was its largest product and service line, bringing in $271.91M (99.9% of the total), followed by Other Revenue at $394.00K (0.1%).
Product Sales Net was Harrow's largest product and service line in fiscal 2025, bringing in $271.91M, or 99.9% of the $272.30M total across its two product and service lines.
Branded was Harrow's largest segment in fiscal 2025, bringing in $195.76M, or 71.9% of the $272.30M total across its two segments.
Branded grew faster than Imprimisrx in fiscal 2025, up 68.6% from $116.12M to $195.76M. Imprimisrx fell 8.3% to $76.55M.
Every figure comes from Harrow's annual financial filings, as reported. Each line keeps the name Harrow gives it, and years follow its fiscal calendar.
Harrow's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.